IL-6 was significantly higher among the chemotherapy than vehicle groups at all time points (Figure 1D; p < 0.0001), suggesting a sustained effect of chemotherapy on this cytokine, as has been noted in breast cancer patients undergoing doxorubicin plus cyclophosphamide treatment [31]. This evidence concerns the gene IL6 and breast carcinoma.